Welcome to our dedicated page for Shattuck Labs SEC filings (Ticker: STTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company focused on autoimmune, inflammatory, and other immune-mediated diseases. Through these filings, investors can review how the company reports material events, financing transactions, and governance changes that affect holders of STTK common stock.
Shattuck’s Form 8-K current reports provide details on topics such as private placements of common stock and warrants, the terms of securities purchase agreements, and related registration rights agreements. These filings describe the structure of pre-funded warrants and common warrants, exercise price provisions, beneficial ownership limitations, and expected gross proceeds, as well as the company’s plans to register resales of the underlying shares.
Other 8-K filings furnish press releases announcing quarterly financial results, including research and development and general and administrative expenses, collaboration or license revenue, and net loss figures. While these press releases are often furnished rather than filed for Exchange Act purposes, they offer insight into Shattuck’s cash position and its expectations about how long existing capital and financing arrangements may support operations, subject to the risks noted in its periodic reports.
Filings also address governance matters, such as the resignation and appointment of directors, changes in board size, and committee assignments. For example, Shattuck has reported the addition of new directors associated with a significant private placement and described the rights of certain investors to designate board members under letter agreements.
By reviewing these SEC documents alongside AI-powered summaries, readers can quickly understand the key terms of Shattuck’s financings, the regulatory status of its securities, and the corporate actions that shape its capital structure and oversight. This filings archive complements Shattuck’s scientific and clinical disclosures by showing how those activities are reflected in its official regulatory reporting.
Shattuck Labs, Inc. provides an annual business update focused on its DR3/TL1A antibody platform for inflammatory and immune‑mediated diseases. The company’s lead program, SL‑325, is a high‑affinity DR3‑blocking monoclonal antibody in a randomized Phase 1 SAD/MAD trial in healthy volunteers, with enrollment expected to complete in the second quarter of 2026 and a Phase 2 Crohn’s disease trial planned for the third quarter of 2026.
Preclinical GLP studies in non‑human primates showed full, durable DR3 receptor occupancy at doses as low as 1 mg/kg and a no‑observed‑adverse‑effect level at 100 mg/kg, supporting extended dosing intervals. Shattuck is also advancing SL‑425, a half‑life‑extended DR3 antibody, and multiple preclinical DR3‑based bispecific antibodies, while emphasizing intellectual property, outsourced cGMP manufacturing, and detailed compliance with U.S. and international biologics regulations.
Shattuck Labs, Inc. reported fourth quarter and full-year 2025 results and updated its development and cash outlook. The company is advancing SL-325, a potential first-in-class DR3 blocking antibody, with Phase 1 data expected in the second quarter of 2026 and a Phase 2 Crohn’s disease trial planned for the third quarter of 2026.
R&D expenses fell to $35.3 million in 2025 from $67.2 million in 2024, mainly due to discontinuation of the SL-172154 program and workforce reductions, while G&A decreased to $17.2 million from $19.1 million. Net loss narrowed to $48.8 million, or $0.70 per share, from $75.4 million, or $1.49 per share, in the prior year.
Cash, cash equivalents and short-term investments were approximately $78.1 million as of December 31, 2025, and about $94.5 million as of February 28, 2026 including $21.4 million of gross proceeds from at-the-market stock sales. Based on current plans and assuming full warrant exercise, Shattuck expects its capital to fund operations into 2029.
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting beneficial ownership of 7,373,891 shares of Shattuck Labs Inc common stock, representing 11.7% of the class.
The firm reports sole voting and sole dispositive power over all reported shares and certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Shattuck Labs.
Shattuck Labs, Inc. has set its 2026 annual meeting of stockholders for Thursday, May 28, 2026. The meeting date is more than 30 days earlier than the prior year’s meeting, so previously disclosed deadlines for stockholder proposals and director nominations no longer apply.
The company will provide revised deadlines in connection with the 2026 annual meeting, and any stockholder proposals or nominations must comply with SEC Rule 14a-8 and the company’s Bylaws. Full details will appear in upcoming proxy materials to be filed with the SEC.
Shattuck Labs Chief Medical Officer reports share disposition
Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, reported a transaction in the company’s common stock. On 01/25/2026, 3,195 shares of common stock were disposed of in a transaction coded "F" at a price of $4.15 per share. Following this transaction, Pandite beneficially owns 196,219 shares of Shattuck Labs common stock in direct ownership form.
Shattuck Labs, Inc. insider transaction: Company officer Stephen Stout, who serves as General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer, reported a disposition of 593 shares of Shattuck Labs common stock on 01/25/2026 at a price of $4.15 per share. After this transaction, he beneficially owned 81,529 shares of common stock in direct ownership form.
Shattuck Labs, Inc. Chief Business Officer Casi DeYoung reported a small share disposition in company stock. On 01/25/2026, DeYoung disposed of 2,286 shares of Shattuck Labs common stock at a price of $4.15 per share in a transaction coded "F," which typically reflects a disposition reported on a Form 4. Following this transaction, DeYoung directly beneficially owned 73,480 shares of Shattuck Labs common stock.
Shattuck Labs Chief Financial Officer Andrew R. Neill reported a small change in his holdings of Shattuck Labs, Inc. common stock. On January 25, 2026, he disposed of 2,589 shares of common stock in a transaction reported under SEC transaction code "F" at a reported price of $4.15 per share. Following this transaction, Neill beneficially owns 228,224 shares of Shattuck Labs common stock, held directly.
Shattuck Labs, Inc. entered into a sales agreement with Leerink Partners LLC to sell up to $75,000,000 of its common stock through an at-the-market equity program under an effective Form S-3 shelf registration. Shares may be sold from time to time at market prices, and the company is not obligated to sell any amount and can suspend or terminate the program.
Leerink Partners will act as sales agent and earn a commission of up to 3.0% of the gross sales price of any shares sold, plus reimbursed expenses. Shattuck Labs plans to use any net proceeds to fund ongoing and planned clinical trials, develop additional product candidates, and for working capital and general corporate purposes.
Shattuck Labs, Inc. is establishing an at-the-market stock offering program, registering shares of its common stock with an aggregate offering price of up to $75,000,000. The shares may be sold from time to time through Leerink Partners, which will act as sales agent on a commercially reasonable efforts basis and receive a commission of up to 3.0% of the gross sales price per share.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol STTK, with a last reported sale price of $4.44 per share on January 21, 2026. Shattuck Labs is a biotechnology company developing treatments for inflammatory and immune‑mediated diseases, including its lead antibody program SL‑325. Net proceeds from any sales under this program are expected to fund ongoing and planned clinical trials, advancement of additional product candidates, and general corporate and working capital needs, but the company is not obligated to sell any specific amount.